AbolerIS Pharma

/ 1 Rue Gaston Veil
44000 Nantes
FR
AbolerIS Pharma
Foundation date
28/11/2019
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.
IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.
Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.
Upcoming events
All events-
0310 '23
-
1810 '23
EMDS2023@VIB
Event by: VIB -
1212 '23
BioFIT 2023
Event by: Eurasanté
Latest news
More news-
argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis
Thursday September 21st 2023
Read more
-
Galapagos appoints Simon Sturge to its Board of Directors
Tuesday September 19th 2023
Read more
-
13th Investment for HERAN Partners: Broken String Biosciences (UK)
Tuesday September 19th 2023
Read more
Jobs
More jobs-
23/09/23
East Flanders
ERC-funded postdoc position on inter-organelle communication during plant biotic stress responses
Permanent
VIB -
21/09/23
East Flanders
Technician Protein Production and Characterization
Permanent
Orionis Biosciences -
20/09/23
Flemish Brabant
Lab Technician in the Lab for Tumor Inflammation and Angiogenesis
Permanent
VIB